British Biologics Manufacturers: Growth Guide (2026)

British biologics manufacturers sit inside one of the most concentrated life sciences clusters on the planet, yet most still sell the way it was done in 2005. The UK exported over £24.6 billion in pharmaceutical products in 2024, and biologics are the fastest-growing share. UK CDMOs have the facilities and the science. What most lack is a repeatable, scalable way to get their capacity in front of the right buyers before a European competitor does.

Why British biologics manufacturing is a global force

The UK life sciences sector employed 304,200 people and generated £108.1 billion in turnover in 2021/22, according to the Government’s Life Sciences Sector Plan. That base continues to grow. The sector could expand by £41 billion (165%) by 2035 if current policy conditions improve, the same plan projects.

Within that ecosystem, biologics manufacturing is now the fastest-growing CDMO segment globally. Mammalian platforms account for 61.68% of global biologics CDMO revenues, according to Mordor Intelligence’s 2026 biologics CDMO analysis. That number reflects the dominance of monoclonal antibodies, which require glycosylation-specific manufacturing that only mammalian systems can deliver.

The UK has a dense cluster of exactly this kind of capacity.

Lonza’s Slough facility has been manufacturing therapeutic monoclonal antibodies under FDA licence since the mid-1980s. It is one of the oldest continuously operating biologics CDMOs in the world. The company secured $30 million (£24 million) from the UK Department for Science, Innovation and Technology to relocate and expand its UK site to Thames Valley Park near Reading, with a new facility designed for next-generation cell and gene therapy production alongside mAbs. The funding was reported by industry news service IMAPAC in its coverage of UK biologics investment.

Oxford Biomedica (OXB) is the UK’s most prominent specialist in lentiviral and AAV gene therapy vectors. In 2025, OXB turned its first full-year operating profit, with revenues growing roughly 42% to £127-129 million in 2024 and a contracted order backlog of approximately £186 million at year end. According to their full-year trading update, one US-based client preparing for late-stage CAR-T commercial launch secured dedicated space at OXB’s Oxford facility. That is the commercial reality: large clients lock in capacity years before they need it, and the CDMO that already has the relationship wins.

Fujifilm Diosynth Biotechnologies operates from Billingham in County Durham, with a global expansion programme targeting a quadrupling of mammalian bioreactor capacity. The CEO characterised 2025 as the company’s biggest year yet in what Fierce Pharma described as an $8 billion-plus infrastructure drive. The UK site is a core node in that global CDMO network.

AstraZeneca’s Cambridge campus is the headquarters of its BioPharmaceutical Development function. The site covers antibody discovery and protein engineering through to downstream purification for monoclonal antibodies. Cambridge is not a contract manufacturer. It is the engine room for one of the world’s largest biologics pipelines.

CPI’s National Biologics Manufacturing Centre in Darlington offers publicly funded CDMO capability for earlier-stage biologics, covering mammalian cell expression, viral vectors, and microbial platforms. The centre has received $38 million in public investment and is particularly useful for UK biotech companies bridging from development to commercial-scale production.

The government has bet big on biologics manufacturing

The July 2025 Life Sciences Sector Plan is explicit about prioritising manufacturing capacity. The £520 million Life Sciences Innovative Manufacturing Fund exists specifically to subsidise capital investment in UK pharmaceutical manufacturing, with biologics a priority category given their complexity and the strategic importance of supply chain resilience.

This matters commercially because it signals sustained government backing for the sector and creates a tailwind for companies building or expanding UK biologics capacity. CDMOs and specialist manufacturers with strong track records can access grant funding to reduce their cost base and improve pricing competitiveness.

The flip side is that the ABPI’s 2025 survey, titled A Year of Uncertainty, found that foreign direct investment into UK life sciences had dropped 58% between 2017 and 2023, from £1.89 billion to £795 million. Several major companies paused or cancelled planned UK investments, including a £200 million AstraZeneca Cambridge development. The Sector Plan is partly a response to this decline. It signals intent but the commercial conditions that drive inward investment are still being worked out.

For UK biologics manufacturers, this context creates a specific commercial opportunity: international pharmaceutical companies that want UK manufacturing capabilities are actively looking, but the UK needs to do a better job of putting the right suppliers in front of them before European competitors do.

How British biologics manufacturers find clients today

The buyer journey in biologics manufacturing is long. Pharma companies selecting a CDMO for a Phase II programme or a commercial mAb batch may spend 12-18 months evaluating suppliers. Most of that process starts through the same small set of channels.

Trade fairs and industry conferences

BioProcess International (BPI) and CPhI are the dominant deal-starting venues for biologics CDMOs. CPhI Frankfurt 2025 drew more than 60,000 attendees and 2,000 exhibitors. BPI brings together 3,000+ scientists and executives specifically focused on biopharmaceutical production.

For UK CDMOs, attending BPI and CPhI is not optional. But the economics are punishing. A quality exhibition stand, travel, accommodation and the time of senior technical staff can easily reach £80,000-£150,000 per event. The expected outcome is meetings that may or may not progress. Return on that spend is almost impossible to calculate.

Meanwhile, most CDMO decision-makers at a trade fair spend their time defending existing relationships and meeting companies that already know each other. New CDMO relationships rarely start cold at a booth. They start when a pharma company’s technical team has already heard of the supplier and wants a deeper conversation.

Key opinion leader networks and scientific relationships

Academic collaborations, shared conference panels, and co-authorship drive many early CDMO relationships. A biotech company’s head of manufacturing builds their CDMO shortlist from the literature and from their own scientific networks, not from trade fair booths.

This is a slow channel with a ceiling. It favours CDMOs with deep academic roots and long histories. For newer facilities or those trying to reach international clients outside the UK scientific community, it offers limited reach.

Field sales and business development teams

Most UK biologics CDMOs maintain a small BD team, typically 2-5 people covering major pharma markets in Europe and North America. This is expensive. A senior BD director covering the US market costs £120,000-£180,000 in salary alone before travel, bonuses and support costs. That same person has a hard ceiling: a finite number of conferences, a finite number of accounts they can actively manage.

The economics of field sales for a specialised biologics CDMO are brutal. Each qualified lead costs somewhere between £400 and £1,000 in BD resource time and expenses before any sale is made.

Distributor and broker networks

Some CDMOs use intermediaries to reach markets where they have no direct presence. Brokers typically take 5-15% margin on deal values, which erodes the economics significantly on large, multi-year manufacturing contracts. Worse, the CDMO cedes visibility into the client relationship, making it harder to expand or defend the account over time.

Why conventional channels are getting more expensive and less effective

The global biologics CDMO market is projected to grow from $27 billion in 2026 to $38 billion by 2031, according to Mordor Intelligence. That is a large market, but the number of CDMOs chasing it is growing faster than the market itself.

CPhI Frankfurt 2025 had over 2,000 exhibitors. A decade ago, half that number were at comparable events. Every additional CDMO attending BPI or CPhI makes each exhibitor harder to notice. The attention of pharmaceutical development and manufacturing teams is finite. There are more voices competing for it every year.

Field sales costs are rising. Travel costs are rising. The average BD conversion timeline in biologics manufacturing is long and getting longer as pharma companies use more rigorous qualification processes before inviting suppliers into their supply chains. This is particularly true for cell and gene therapies, where quality system audits can take 6-12 months before a contract is signed.

Trade fairs cost, conservatively, £300-£900 per qualified lead when total event costs are divided by leads that actually progress. Field sales reps cost £500-£1,200 per qualified lead, including salary, travel and support overhead.

These costs scale linearly. Hiring a second BD director doubles the cost. Booking a second exhibition doubles the cost. There is no compounding benefit.

What competitive British biologics manufacturers are doing differently

The UK biologics manufacturers winning international contracts at scale are investing in systematic outreach alongside traditional channels, not instead of them.

Systematic outreach means identifying pharmaceutical companies whose pipeline stage and manufacturing complexity actually match a given CDMO’s capabilities, then contacting the right decision-makers (VP Process Development, Head of Manufacturing) with messages relevant to their specific situation. It means doing this across 50 or 100 target companies, not the 15 you happen to meet at a conference.

This is where AI-powered outbound becomes strategically relevant for British biologics manufacturers. papaverAI’s Growth Engine builds and runs outbound systems that identify high-fit prospects, research each company’s specific situation, and send personalised outreach that reaches decision-makers rather than landing in a spam folder.

The economics compare favourably with the alternatives. papaverAI’s cost per qualified lead runs $150 to $300, and unlike trade fairs or field sales, the cost per lead decreases over time as the system learns which messages and which prospect profiles convert best. There is no linear scaling problem. Learn more about how this works.

This does not replace BPI or CPhI attendance. It makes attendance more effective. The companies you meet at a conference have often received an outbound message from you 3-4 weeks earlier and already have context before they walk up to your booth.

The biosimilars opportunity adds commercial complexity

UK-based biologics manufacturers are increasingly fielding interest from biosimilar developers looking for CDMO partners as major monoclonal antibody patents expire. The global biosimilars CDMO opportunity is real: according to Mordor Intelligence’s biologics CDMO analysis, biosimilars are growing at an 8.72% CAGR while the originator biologics segment grows more slowly.

The NHS is one of the most aggressive early adopters of biosimilars in Europe, driven by cost pressure. This creates domestic demand for biosimilar manufacturing capacity but also complicates the commercial picture for UK CDMOs. Biosimilar contracts are often structured differently from originator contracts, with tighter margins and more aggressive timelines. The CDMOs that succeed in biosimilars tend to be those with highly efficient, well-optimised manufacturing processes rather than those competing on facility newness alone.

For UK biosimilar-focused manufacturers, the commercial opportunity is real but the competition is intense. European CDMOs in Germany, Switzerland, and the Netherlands are equally active in chasing biosimilar development contracts. UK facilities need to present their capability actively to the 200-500 biosimilar developers globally who are making CDMO selection decisions, not wait to be discovered.

FAQ

Who are the main British biologics manufacturers and CDMOs?

The most prominent are Lonza (Slough, relocating to Reading), Oxford Biomedica (Oxford, gene therapy vectors), Fujifilm Diosynth Biotechnologies (Billingham, mammalian biologics), and CPI’s National Biologics Manufacturing Centre (Darlington). AstraZeneca anchors R&D biologics capability in Cambridge. The UK also has dozens of smaller specialist CDMOs and bioprocess development companies.

What is the UK Government’s Life Sciences Innovative Manufacturing Fund?

It is a £520 million grant programme announced in the July 2025 Life Sciences Sector Plan, designed to subsidise capital investment in UK pharmaceutical manufacturing. CDMOs and biologics manufacturers can apply for grants to fund facility expansion, new equipment, or technology upgrades. The goal is to make the UK more attractive for manufacturing investment and to build supply chain resilience for critical medicines.

How do UK biologics CDMOs typically find new clients?

Most rely on a combination of trade fair attendance (BPI, CPhI), key opinion leader networks, a small field sales team, and inbound enquiries from their website and publications. These channels are effective but expensive and slow. The average CDMO BD cycle from initial contact to signed contract can run 12-24 months.

What does an AI-powered outbound system do for a biologics CDMO?

It identifies pharmaceutical companies whose pipeline matches the CDMO’s capabilities and sends personalised outreach to the relevant decision-makers. The research on each prospect is done automatically. The system runs continuously and covers far more potential clients than a field sales team can reach manually. See how papaverAI’s approach works and the broader Growth Engine framework.

How does the UK biologics sector fit within the broader UK pharmaceutical export picture?

UK pharma exports total over £24.6 billion per year, making the sector the country’s third-largest goods export. Biologics are the highest-value and fastest-growing segment, spanning everything from monoclonal antibodies and vaccines to gene therapies. For more on the UK pharma and biotech commercial landscape, read our overview of UK pharma and biotech exporters.

---

UK biologics manufacturers have strong science and real government backing now. The constraint is visibility. Pharmaceutical companies choosing CDMOs in the next 12 months will shortlist the suppliers whose names they already know. Explore how the papaverAI Growth Engine helps manufacturers get in front of the right buyers, or check the broader context for UK manufacturing exporters.